KR20240119163A - 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물 - Google Patents

확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물 Download PDF

Info

Publication number
KR20240119163A
KR20240119163A KR1020247024828A KR20247024828A KR20240119163A KR 20240119163 A KR20240119163 A KR 20240119163A KR 1020247024828 A KR1020247024828 A KR 1020247024828A KR 20247024828 A KR20247024828 A KR 20247024828A KR 20240119163 A KR20240119163 A KR 20240119163A
Authority
KR
South Korea
Prior art keywords
compound
mmol
piperidine
sulfonyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024828A
Other languages
English (en)
Korean (ko)
Inventor
조안 오슬롭
다니엘레 오벨레
재 킴
로버트 맥도웰
용홍 송
아빈더 스랜
민 종
Original Assignee
미요카디아, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미요카디아, 인크. filed Critical 미요카디아, 인크.
Publication of KR20240119163A publication Critical patent/KR20240119163A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247024828A 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물 Pending KR20240119163A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562106571P 2015-01-22 2015-01-22
US62/106,571 2015-01-22
KR1020237033324A KR102688851B1 (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물
PCT/US2016/014365 WO2016118774A1 (en) 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033324A Division KR102688851B1 (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물

Publications (1)

Publication Number Publication Date
KR20240119163A true KR20240119163A (ko) 2024-08-06

Family

ID=55275230

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247024828A Pending KR20240119163A (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물
KR1020177022900A Active KR102585550B1 (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물
KR1020237033324A Active KR102688851B1 (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177022900A Active KR102585550B1 (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물
KR1020237033324A Active KR102688851B1 (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물

Country Status (36)

Country Link
US (1) US9925177B2 (https=)
EP (2) EP4234017B1 (https=)
JP (1) JP6712275B2 (https=)
KR (3) KR20240119163A (https=)
CN (3) CN107428719B (https=)
AU (4) AU2016209200B2 (https=)
BR (1) BR112017015627B1 (https=)
CA (1) CA2974370C (https=)
CL (1) CL2017001871A1 (https=)
CO (1) CO2017008398A2 (https=)
CR (1) CR20170370A (https=)
DK (1) DK3247707T3 (https=)
DO (2) DOP2017000166A (https=)
EA (1) EA036923B1 (https=)
EC (1) ECSP17054181A (https=)
ES (1) ES2953480T3 (https=)
FI (1) FI3247707T3 (https=)
GT (1) GT201700163A (https=)
HR (1) HRP20230737T1 (https=)
HU (1) HUE063410T2 (https=)
IL (6) IL295547A (https=)
LT (1) LT3247707T (https=)
MX (3) MX394704B (https=)
MY (1) MY203427A (https=)
PE (2) PE20171511A1 (https=)
PH (2) PH12021553074A1 (https=)
PL (1) PL3247707T3 (https=)
PT (1) PT3247707T (https=)
RS (1) RS64432B1 (https=)
SG (2) SG10201913047UA (https=)
SI (1) SI3247707T1 (https=)
SM (1) SMT202300259T1 (https=)
TN (1) TN2017000320A1 (https=)
UA (1) UA119905C2 (https=)
WO (1) WO2016118774A1 (https=)
ZA (1) ZA201704777B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
PE20200924A1 (es) 2017-09-13 2020-09-14 Amgen Inc Compuestos de bisamida sustituida que activan el sarcomero cardiaco
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
CA3090204A1 (en) 2018-02-01 2019-08-08 MyoKardia, Inc. Pyrazole compounds and preparation thereof
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
GB201905520D0 (en) 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
KR20220009440A (ko) * 2019-05-19 2022-01-24 미요카디아, 인크. 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료
CN114127061A (zh) 2019-07-16 2022-03-01 迈奥卡迪亚公司 (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
EP4146205A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS
WO2021257456A1 (en) * 2020-06-15 2021-12-23 MyoKardia, Inc. Treatment of atrial dysfunction
KR102541297B1 (ko) 2020-08-18 2023-06-09 가톨릭대학교 산학협력단 확장성 심근병 모델 및 이의 제조방법
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
WO2025244956A1 (en) 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250789A1 (en) 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
ES2522579T3 (es) * 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
TWI472331B (zh) * 2009-11-11 2015-02-11 Sumitomo Dainippon Pharma Co Ltd ８－氮雙環〔３‧２‧１〕辛烷－８－羧醯胺衍生物

Also Published As

Publication number Publication date
MY203427A (en) 2024-06-27
EP4234017A2 (en) 2023-08-30
LT3247707T (lt) 2023-08-25
MX2022007040A (es) 2022-06-24
GT201700163A (es) 2018-10-18
CN107428719A (zh) 2017-12-01
AU2020244490B2 (en) 2022-12-01
US9925177B2 (en) 2018-03-27
EA036923B1 (ru) 2021-01-15
IL253552B (en) 2019-12-31
DK3247707T3 (da) 2023-07-03
CR20170370A (es) 2017-10-20
CN107428719B (zh) 2020-03-27
JP6712275B2 (ja) 2020-06-17
SG10201913047UA (en) 2020-02-27
WO2016118774A1 (en) 2016-07-28
PL3247707T3 (pl) 2023-12-11
CL2017001871A1 (es) 2018-04-13
AU2016209200B2 (en) 2020-07-02
BR112017015627A2 (pt) 2018-03-13
KR102585550B1 (ko) 2023-10-10
FI3247707T3 (fi) 2023-08-22
JP2018502883A (ja) 2018-02-01
IL271034A (en) 2020-01-30
DOP2022000172A (es) 2022-09-30
SG11201705928XA (en) 2017-08-30
MX2021010778A (es) 2022-08-11
CN111393414A (zh) 2020-07-10
AU2023200361A1 (en) 2023-02-23
HK1246775A1 (en) 2018-09-14
IL253552A0 (en) 2017-09-28
AU2024266781A1 (en) 2024-12-12
NZ734020A (en) 2023-11-24
PH12017501279A1 (en) 2018-01-29
KR20170113578A (ko) 2017-10-12
PH12017501279B1 (en) 2023-06-16
BR112017015627B1 (pt) 2022-11-16
ZA201704777B (en) 2023-07-26
TN2017000320A1 (en) 2019-01-16
CN111393414B (zh) 2024-05-07
PE20212253A1 (es) 2021-11-24
AU2016209200A1 (en) 2017-08-10
CA2974370C (en) 2023-10-31
HRP20230737T1 (hr) 2023-10-13
PH12021553074A1 (en) 2023-03-06
IL295547A (en) 2022-10-01
EP4234017B1 (en) 2026-04-15
MX394704B (es) 2025-03-24
EP4234017A3 (en) 2023-10-18
SMT202300259T1 (it) 2023-09-06
RS64432B1 (sr) 2023-09-29
PE20171511A1 (es) 2017-10-20
US20160243100A1 (en) 2016-08-25
IL279247A (en) 2021-01-31
AU2020244490A1 (en) 2020-10-29
KR102688851B1 (ko) 2024-07-29
IL313678A (en) 2024-08-01
SI3247707T1 (sl) 2023-10-30
UA119905C2 (uk) 2019-08-27
AU2023200361B2 (en) 2024-08-22
KR20230145504A (ko) 2023-10-17
CA2974370A1 (en) 2016-07-28
CO2017008398A2 (es) 2017-10-31
EP3247707B1 (en) 2023-05-31
ES2953480T3 (es) 2023-11-13
EP3247707A1 (en) 2017-11-29
HUE063410T2 (hu) 2024-01-28
MX2017009540A (es) 2017-10-20
DOP2017000166A (es) 2017-10-15
PT3247707T (pt) 2023-08-31
IL286369A (en) 2021-10-31
CN118164961A (zh) 2024-06-11
ECSP17054181A (es) 2019-02-28
EA201791656A1 (ru) 2017-11-30
MX385960B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
KR102688851B1 (ko) 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물
US20250275952A1 (en) 4-methylsulfonyl-substituted piperidine urea compounds
AU2019228568A1 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
HK40100462A (en) 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
JPH11315020A (ja) 環状アミン誘導体を含有する医薬
HK40027481A (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
HK1246775B (en) 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
HK40112260A (zh) 用於治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
HK40027481B (zh) 用於治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
NZ772098B2 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240723

Application number text: 1020237033324

Filing date: 20230926

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240822

Comment text: Request for Examination of Application